Table 3.
| Subgroups | Response rates | EFS/PFS/TTP | OS from transplant | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Study design | Age group |
Sample size |
Melphalan dose | CR | P value |
Median(months) | P value | Median(months) | P value |
| Merz (21) | Retrospective cohort study |
60–64 | 83 | 100–200 mg/m2 | 38%(nCR+CR) | NS | EFS 27 | NS | Not reached | NS |
| 65–69 | 93 | 33%(nCR+CR) | EFS 23 | Not reached | ||||||
| 70–75 | 26 | 31%(nCR+CR) | EFS 23 | Not reached | ||||||
| Muta (11) | Retrospective cohort study |
51–64 | 63 | 100–200 mg/m2 | 24% | 0.06 | PFS 20.8 | 0.26 | 72.5 | 0.07 |
| 65–76 | 25 | 12% | PFS 17.1 | 40.8 | ||||||
| El Cheikh (9) | Retrospective cohort study |
60–65 | 104 | 100–200 mg/m2 | 48% CR or VGPR |
0.58 | PFS 45 | <0.0001 | 5 Yr OS 57% | NS |
| 65–77 | 82 | 41% CR or VGPR |
PFS 27 | 5Yr OS 54% | ||||||
| Kumar (22) | Matched pair analysis |
37–64 | 60 | 140–200 mg/m2 | 28% | NS | TTP 17.8 | 0.07 | 53.3 | NS |
| 70–75 | 33 | 42% | TTP 28.5 | Not reached | ||||||
| Gertz (23) | Retrospective cohort study |
≤65 | 541 | 140–200 mg/m2 | 30% | NS | TTP 17 | 0.09 | 44 | 0.28 |
| >65 | 137 | 40% | TTP 17 | 44 | ||||||
|
Jantunen (36) |
Retrospective cohort study |
39–64 | 79 | 200 mg/m2 | 36% | NR | PFS 21 | NS | 66 | NS |
| 65–73 | 22 | 44% | PFS 23 | 57 | ||||||
| Krejci (24) | Retrospective cohort study |
31–60 | 103 | 140–200 mg/m2 | NR | NR | 25.7 | 0.002 | ||
| 66–69 | 30 | NR | NR | 71 | ||||||
| Terpos (37) | Retrospective cohort study |
27–60 | 95 | 100–200 mg/m2; 140mg/m2+/−TBI |
NR | NR | 50.4 | 0.57 | ||
| 61–70 | 32 | NR | NR | 37.6 | ||||||
| Reece (38) | Registry | 30–59 | 382 | Several doses/regimens +/− TBI |
34% | NS | 3Yr PFS 44% |
NS | 3Yr OS 55% | NS |
| 60–73 | 110 | 33% | 3Yr PFS 35% |
3Yr OS 58% | ||||||
| O’Shea (39) | Retrospective cohort study |
26–60 | 151 | 100–200 mg/m2; 140mg/m2+/−TBI |
NR | NR | 50.9 | NS | ||
| 61–72 | 60 | NR | NR | 48.3 | ||||||
| Lenhoff (25) | Population- based registry |
<60 | 294 | 200mg/m2 | 36% | NS | EFS 36 | 0.005 | 67 | 0.004 |
| 60–64 | 120 | 37% | EFS 24 | 48 | ||||||
ASCT, autologous stem cell transplant; EFS, event-free survival; PFS, progression-free survival; OS, overall survival; CR, complete response; nCR, near complete response; VGPR, very good partial response; NS, nonsignificant; TTP, time to progresion; NR, not reported; TBI, total body irradiation.